Skip to main content

bluebird bio, Inc.

BLUEDelisted Jun 2, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001293971

bluebird bio, Inc. was delisted on Jun 2, 2025; its insiders filed their last Form 4 on Jun 3, 2025; 85 institutions reported holding it in 13F filings for Q1 2025, worth $17.1M in total; no superinvestor held it.

Q2 2023 vs. Q1 2023

How the institutions holding bluebird bio, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of BLUE: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders180177−3
Shares97.3M93.8M−3.55M (−3.6%)
Value$309.5M$308.6M−$971.1K (−0.3%)

New holders (26)

Institutions that held bluebird bio, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to BLUE in Q2 2023
InstitutionSharesValue% of portfolio
Walleye Capital LLC836,760$2.75M0.05%
Renaissance Technologies LLC550,200$1.81M0.00%
Lion Point Capital, LP531,256$1.75M1.30%
Cubist Systematic Strategies, LLC373,488$1.23M0.01%
Healthcare of Ontario Pension Plan Trust Fund353,000$1.16M0.01%
ExodusPoint Capital Management, LP271,627$894.0K0.01%
Two Sigma Investments, LP168,593$554.7K0.00%
HRT Financial LP113,093$372.0K0.00%
Graham Capital Management, L.P.95,052$312.7K0.01%
Point72 Middle East FZE63,352$208.4K0.01%
Caxton Associates LP52,925$174.1K0.03%
GTS Securities LLC41,554$136.7K0.00%
Dynamic Technology Lab Private Ltd34,654$114.0K0.01%
D. E. Shaw & Co., Inc.32,960$108.4K0.00%
Jefferies Financial Group Inc.31,453$103.5K0.00%
Sargent Investment Group, LLC24,324$80.0K0.02%
Marshall Wace, LLP19,700$64.8K0.00%
Channel Wealth LLC12,500$41.1K0.02%
Financial Advocates Investment Management11,450$39.3K0.00%
Caption Management, LLC10,000$32.9K0.01%
Headlands Technologies LLC6,264$20.6K0.01%
Harbor Capital Advisors, Inc.3,787$12.5K0.00%
Impact Partnership Wealth, LLC167$5490.00%
Huntington National Bank124$4080.00%
St Germain D J Co Inc57$1880.00%
Coppell Advisory Solutions LLC1,350––

Sold out (29)

Institutions that held bluebird bio, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.